WO1991000108A1 - Antibody-oxidase conjugates with non-systemic substrates - Google Patents

Antibody-oxidase conjugates with non-systemic substrates Download PDF

Info

Publication number
WO1991000108A1
WO1991000108A1 PCT/US1990/001527 US9001527W WO9100108A1 WO 1991000108 A1 WO1991000108 A1 WO 1991000108A1 US 9001527 W US9001527 W US 9001527W WO 9100108 A1 WO9100108 A1 WO 9100108A1
Authority
WO
WIPO (PCT)
Prior art keywords
oxidase
cells
target cell
binding protein
conjugate
Prior art date
Application number
PCT/US1990/001527
Other languages
French (fr)
Inventor
John D. Duncan
Frieder K. Hofmann
Original Assignee
Brunswick Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brunswick Corporation filed Critical Brunswick Corporation
Publication of WO1991000108A1 publication Critical patent/WO1991000108A1/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]

Definitions

  • the technical field of the present application relates to conjugates of antibodies and enzymes, linked together by linker molecules, which are designed for therapeutic purposes.
  • enzyme-immunoconjugates composed of any antibody or fragment thereof linked to an oxidase for which the natural substrate is not normally present in the body fluids or otherwise available in the extracellular spaces of the body.
  • Monoclonal antibodies specific for epitopes unique to certain types of cancer cells, T cell, B cells, and the like have been identified and are proposed for delivery of drugs directly and specifically to the target cells. Specificity, and thus amelioration of side effects, depends upon two factors: the specificity and tenacity of attachment to the target; and the effects of freely circulating (not attached) agent on non-target tissues in the body. These two factors are interrelated due to the fact that any binding agent, regardless of how strong the bond is, is in some state of equilibrium with the lymph and blood. Also, during administration, either intraperitoneally or intravenously, there will be a high concentration of freely circulating toxic agent until it is bound to the target cells or cleared by the liver and/or kidneys or the lymphocytes. This clearing process relieves the burden of freely circulating toxic agent, but also concentrates the toxic agent in the organs involved.
  • the present invention relates to a novel approach to the problem of targeting toxic agents to cancer cells or other pathogenic cells without a significant degree of side effect on healthy tissue.
  • the present invention involves a class of conjugates for therapeutic use which consist of an enzyme attached to a target cell binding protein.
  • the enzyme can be any which produces a freely diffusible cytotoxic agent when positioned on the exterior of a target cell or organism.
  • the target cell binding protein can be an antibody, either mono- or polyclonal, a fragment of an antibody, or any other molecule with specificity for a specific type of cell, e.g. a tumor cell, or organism.
  • the enzyme can be attached either directly to the target cell binding protein or via a linker molecule designed to provide adequate spacing to prevent steric hindrance.
  • the attachment of the enzyme to the target cell binding protein is preferably stable to all conditions of administration to a patient and to conditions present in the microenvironment at the site of action.
  • the novelty of the present invention lies in the fact that each of the enzymes chosen acts on substrates which are not normal constituents of the environment of the site in the body in which it is expected to function nor through which it passes on its way to that site. Thus the enzyme will be exposed to no substrate and produce no cytotoxic products while circulating in the body enroute to its target.
  • the conjugates of the present invention utilize an oxidase enzyme, attached to tumor-specific monoclonal antibodies or other target binding proteins, to produce hydrogen peroxide as the toxic agent.
  • Hydrogen peroxide is a highly toxic compound capable of causing rapid cell death through membrane disruption. Hydrogen peroxide is freely diffusible in aqueous solution and will rapidly diffuse to the surface of cells adjacent to the enzyme. In addition to being highly water-soluble, hydrogen peroxide also has lipophilic characteristics which give it an affinity for cell membranes which is probably a significant factor in its high toxicity to cells.
  • Hydrogen peroxide has an advantage in therapy over other cytotoxic agents as it is fairly unstable and will be decomposed to water and oxygen by erythrocytes or catalase released from lysed target cells. Therefore, no side reactions from activated agents diffusing away from the generation site are expected. This is in sharp contrast to the pro-drug approach where a modified drug (pro-drug) is rendered active again by action of an enzyme bound to an antibody. Even after cell death, the cell membrane bound enzyme will continue to convert pro-drugs to drugs.
  • One such conjugate is an ethanol oxidase conjugate.
  • Ethanol oxidase is not found in mammals and its substrate, ethanol, is not normally present anywhere in the mammalian body. However, even 0.1% ethanol concentration is sufficient to give good enzymatic turnover.
  • the toxic product of the enzymatic reaction is hydrogen peroxide.
  • Another conjugate is a galactose oxidase conjugate.
  • Galactose oxidase is not found in mammals and its substrate, galactose, can easily be eliminated from normal circulation by normal metabolic pathways. Again, the toxic agent produced is hydrogen peroxide.
  • Another conjugate is a D-amino acid oxidase conjugate.
  • This enzyme and its substrates, the D-amino acids are not found in mammals.
  • the toxic agent produced is hydrogen peroxide.
  • Another conjugate is an ⁇ -glycerol phosphate oxidase conjugate. This enzyme is not found in mammals and its substrate, L- ⁇ -glycerol phosphate, is found only inside of cells, not outside them. This particular conjugate most likely functions by attachment to the exterior of a cell acting upon exogenously added substrate, which does not cross cell membranes.
  • Attachment of the various enzymes to the target cell binding protein may be achieved by a variety of means.
  • PCT Application No. PCT/GB86/00711, filed November 21, 1986, published June 4, 1987, Publication No. WO 87/03205, Starkie - inventor and European Patent No. 0 088 695, to Cytogen both disclose such means.
  • the preferred aspect of such attachment is that it is preferably stable to the physiological conditions present during administration to a patient and transport to the site of action.
  • the attachment is preferably stable to the conditions present at the site of action, particularly to the concentration of hydrogen peroxide present in the immediate vicinity when the enzyme is fully functional. Covalent attachment of the enzyme to a linker molecule is preferable for such stability.
  • linking reactions are preferably achieved at a position on the enzyme and under conditions which do not affect the function of the catalytic site of the enzyme and on the antibody at a site which maintains the specificity and affinity of the antigen binding site.
  • the linker molecule may be of a variety of types depending upon the specific sites of attachment to the enzyme and the antibody. The preferred features are that the bond formed is preferably stable to all conditions which the therapeutic agent encounters and that the linker molecule itself preferably does not have reactive groups which would result in its degradation in vivo . The order of reaction would be determined by the specific chemistries of bonding used and could either follow the sequence of attaching the linker to the enzyme and finally to the antibody, or attaching the linker to the antibody followed by attachment to the enzyme.
  • the enzyme-antibody ratio is preferably about 1:1. Excess enzyme is generally to be avoided.
  • An enzyme-linker-antibody conjugate meeting the requirements described above would produce hydrogen peroxide in close proximity to the targeted cell.
  • the hydrogen peroxide produced would be free to diffuse to all adjacent cells. Given the known heterogeneity of tumor cells, this would enhance the effectiveness of such a conjugate as a therapeutic agent.
  • Even highly efficacious, specifically targeted cytotoxic agents which act directly on cells have the shortcoming that they will kill only those cells to which they attach.
  • Surrounding cells which may be neoplastic, but lack the specific epitope targeted will not be killed.
  • the only solution to this problem using this specific targeting technique is to create a bank of antibodies which will locate all tumor cells. This is a more complex solution and may not be possible when small tumor cell populations are involved.
  • the present invention would solve the problem of tumor cell heterogeneity by killing all cell adjacent to targeted cells. Some normal cells may also be killed, but this would be a very minor side effect compared to thorough destruction of all tumor cells.
  • the conjugates are preferably targeted to sites which are not rapidly internalized, since this would not allow for killing of adjacent heterogenous tumor cells and would very likely result in inactivation of the oxidase.
  • These conjugates once attached on the exterior of the cells, preferably utilize substrates which are not normally found in the body fluids filling the extracellular spaces but can diffuse to the site of attachment of the conjugate.
  • substrates can include molecules normally found within cells, but not external to them, molecules not normally found in the body, or molecules found in the body in vivo but normally in low enough concentrations that no toxicity is produced by reaction with the oxidases.
  • a corollary to the requirement that the substrate be not normally found external to cells in the body is that the specific enzyme itself preferably does not occur naturally in humans.
  • the enzyme portion of the conjugate would not produce toxic agent (hydrogen peroxide) until desired.
  • the procedure would involve administering the conjugate into the blood, allowing ample time for the conjugate to seek and attach to its specific target and for excess or unattached conjugate to be cleared from the general circulation by action primarily of the liver and kidneys. After such time, a dose of the enzyme's substrate would be injected into the blood at a concentration adequate for enzyme activity without side effects (if any) in the body from the presence of the substrate.
  • Glycerol phosphate and galactose are normal metabolites and can be administered at a fairly high dose without showing side effects. Although ethanol is not a normal metabolite, it will be metabolized to fat and its side reactions are generally regarded as pleasant. D- amino acids do not normally occur in humans. If at all, only a slight inhibitory reaction of the normal human enzymes which act on the L-amino acid form of the D-amino acid might be expected. This inhibitory reaction could possibly be overcome by simultaneous administration of a higher dose of the equivalent L-amino acid. Treatment regimes can be determined based on the life of the enzyme conjugate, the concentration of the substrate, the reaction rate of the enzyme, and the like.
  • an enzyme-linker conjugate could be prepared as a general agent for attachment to any antibody or antibody fragment of the desired specificity.
  • Polyclonal antibodies to viruses or bacteria, for example, could also be attached in like manner.
  • Specific enzyme-linker conjugates could also be prepared for attachment to other types of target cell binding proteins, such as hormones, growth factors, binding proteins of various types, and the like It would therefore be possible to use the present invention for destroying a certain population of T cells or B cells in the body, for example, or to "purify" a culture of cells by killing a contaminating population having a specific affinity which can be exploited.
  • Such conjugates, using a variety of linkers for various purposes is also an aspect of the present invention.
  • SMCC Derivatization of Antibody To 75 nmol (11.3 mg) of antibody 9.2.27 in 1 ml phosphate buffered saline (pH 7.0) is added 15 ⁇ l of a 25 mM solution of SMCC (succinimidyl-4- (N-maleimidomethyl)- cyclohexane-1-carboxylate) . The reaction is allowed to proceed for one hour at room temperature. The mixture is centrifuged and then gel filtered on a PD-10 column equilibrated in 0.1 M potassium phosphate (pH 6.0). Preparation of conjugate
  • the conjugate mixture is gel filtered on a PD-10 column equilibrated in 10 mM MES (pH 6.0) .
  • the void volume eluate is centrifuged and applied to a column (4 x 1 cm) of S-Sepharose equilibrated in 10 mM MES (pH 6.0).
  • the column is washed with equilibration buffer and the conjugate is eluted with an appropriate eluent depending on the oxidase, e.g. 10 mM MES, 0.2 M NaCl (pH 6.0).
  • an appropriate eluent depending on the oxidase, e.g. 10 mM MES, 0.2 M NaCl (pH 6.0).
  • to the conjugate eluate is added 200 ⁇ l of a 1 mM solution of cofactor for the particular oxidase in the conjugate.
  • the conjugate is further purified by chromatography on a column (60 x 2.6 cm) of Sephacryl S-300 HR equilibrated in 0.1 M potassium phosphate, 0.05 M NaCl
  • each conjugate is assayed and found to be a 1:1 adduct of the enzyme and antibody.
  • Example 1 Each of the conjugates prepared in Example 1 is evaluated for in vitro cytotoxic activity using the following procedure.
  • the immunoconjugate and catalase containing nutrient is removed 30 minutes later and the wells are rinsed three times with the original medium and the cells are allowed to continue to grow in the original medium, to which 2mM of substrate for the conjugate oxidase is added. After 24 hours, 10 ⁇ l of 1 ⁇ Ci - -thymidine containing medium is added in order to measure thymidine uptake. Thymidine is incorporated into DNA and thymidine uptake is used to measure DNA synthesis which relates to cell viability. After another day of growth the plates are shock frozen, then thawed and the individual well contents passed through glass fiber filters. The radioactivity is determined and taken as a measure of cell viability.
  • Each of the conjugates prepared in Example 1 is evaluated for in vivo binding specificity and affinity by the following procedure.
  • Thymus deficient BALBc (nude/nude) mice are subcutaneously injected with 2x10 6 M21-UCLA melanoma cells. After two weeks, 3 ⁇ Ci of I 125 iodinated immunoconjugate is injected into the tail vein. After 48 hours the animals are sacrificed and the radioactivity in individual organs is determined. The immunoconjugates are formed using enzyme and 9.2.27 monoclonal antibody following the procedures discussed in Example 1.
  • the in vivo biodistribution data obtained with tumor bearing nude mice also shows that each conjugate has a high degree of binding specificity and affinity. Further, the data indicates that for each conjugate, any unbound conjugate is cleared from the body as indicated by the low levels of conjugate found in the blood, liver, kidney, spleen and intestine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Enzyme-immunoconjugates which can be used for therapeutic purposes without significant patient side effects due to their administration. The general type of enzyme-immunoconjugate is composed of any antibody or fragment thereof linked to an oxidase whose natural substrate is not normally present in the body fluids or otherwise available in the extracellular spaces of the body. The therapeutic action of such oxidases lies in their ability to produce the cytotoxic yet biologically rapidly degrading agent hydrogen peroxide. Such oxidase-immunoconjugates would be specifically targeted to the desired tissues by use of the antibody component but would not be active until such time as a substrate of exogenous source is administered to the patient, whereupon hydrogen peroxide would be produced by the enzymatic process wherever the oxidase-immunoconjugate is present.

Description

ANTIBODY-OXIDASE CONJUGATES WITH NON-SYSTEMIC SUBSTRATES
TECHNICAL FIELD
The technical field of the present application relates to conjugates of antibodies and enzymes, linked together by linker molecules, which are designed for therapeutic purposes.
More specifically, it relates to therapeutic preparations of enzyme-immunoconjugates composed of any antibody or fragment thereof linked to an oxidase for which the natural substrate is not normally present in the body fluids or otherwise available in the extracellular spaces of the body.
BACKGROUND ART It has long been recognized that therapeutic agents which specifically target invading organisms or diseased cells are highly desirable. Such specific targeting by the biologically active agent allows lower doses to be given and reduces the side effects created by non-specific action of the agent. Specific targeting has previously been restricted to drugs which act by exploitation of biochemical differences between the host and the disease organism. However, the development of techniques for the selection of specific hybridoma cell lines which produce specific monoclonal antibodies, and the subsequent technologies developed for mass production of such monoclonal antibodies, has brought the therapeutic use of targeted drugs in situations where the biochemical properties of the diseased cells are nearly identical to those of healthy cells to the threshold of reality.
Monoclonal antibodies specific for epitopes unique to certain types of cancer cells, T cell, B cells, and the like have been identified and are proposed for delivery of drugs directly and specifically to the target cells. Specificity, and thus amelioration of side effects, depends upon two factors: the specificity and tenacity of attachment to the target; and the effects of freely circulating (not attached) agent on non-target tissues in the body. These two factors are interrelated due to the fact that any binding agent, regardless of how strong the bond is, is in some state of equilibrium with the lymph and blood. Also, during administration, either intraperitoneally or intravenously, there will be a high concentration of freely circulating toxic agent until it is bound to the target cells or cleared by the liver and/or kidneys or the lymphocytes. This clearing process relieves the burden of freely circulating toxic agent, but also concentrates the toxic agent in the organs involved.
Various therapeutic approaches have been proposed involving targeted toxic agents. The glucose oxidase i munoconjugate, for example, has been described in the prior art, particularly in PCT Application No. PCT/GB86/00711, November 21, 1986, published June 4, 1987, Publication No. WO 87/03205, Starkie - inventor. The major problem of all the therapeutic approaches to date is the unspecific killing of non-target cells. The present invention proposes a solution to this problem.
DISCLOSURE OF INVENTION The present invention relates to a novel approach to the problem of targeting toxic agents to cancer cells or other pathogenic cells without a significant degree of side effect on healthy tissue. The present invention involves a class of conjugates for therapeutic use which consist of an enzyme attached to a target cell binding protein. The enzyme can be any which produces a freely diffusible cytotoxic agent when positioned on the exterior of a target cell or organism. The target cell binding protein can be an antibody, either mono- or polyclonal, a fragment of an antibody, or any other molecule with specificity for a specific type of cell, e.g. a tumor cell, or organism. The enzyme can be attached either directly to the target cell binding protein or via a linker molecule designed to provide adequate spacing to prevent steric hindrance. The attachment of the enzyme to the target cell binding protein is preferably stable to all conditions of administration to a patient and to conditions present in the microenvironment at the site of action. The novelty of the present invention lies in the fact that each of the enzymes chosen acts on substrates which are not normal constituents of the environment of the site in the body in which it is expected to function nor through which it passes on its way to that site. Thus the enzyme will be exposed to no substrate and produce no cytotoxic products while circulating in the body enroute to its target.
MODES FOR CARRYING OUT THE INVENTION The conjugates of the present invention utilize an oxidase enzyme, attached to tumor-specific monoclonal antibodies or other target binding proteins, to produce hydrogen peroxide as the toxic agent. Hydrogen peroxide is a highly toxic compound capable of causing rapid cell death through membrane disruption. Hydrogen peroxide is freely diffusible in aqueous solution and will rapidly diffuse to the surface of cells adjacent to the enzyme. In addition to being highly water-soluble, hydrogen peroxide also has lipophilic characteristics which give it an affinity for cell membranes which is probably a significant factor in its high toxicity to cells. Hydrogen peroxide has an advantage in therapy over other cytotoxic agents as it is fairly unstable and will be decomposed to water and oxygen by erythrocytes or catalase released from lysed target cells. Therefore, no side reactions from activated agents diffusing away from the generation site are expected. This is in sharp contrast to the pro-drug approach where a modified drug (pro-drug) is rendered active again by action of an enzyme bound to an antibody. Even after cell death, the cell membrane bound enzyme will continue to convert pro-drugs to drugs.
One such conjugate is an ethanol oxidase conjugate. Ethanol oxidase is not found in mammals and its substrate, ethanol, is not normally present anywhere in the mammalian body. However, even 0.1% ethanol concentration is sufficient to give good enzymatic turnover. The toxic product of the enzymatic reaction is hydrogen peroxide. Another conjugate is a galactose oxidase conjugate.
Galactose oxidase is not found in mammals and its substrate, galactose, can easily be eliminated from normal circulation by normal metabolic pathways. Again, the toxic agent produced is hydrogen peroxide.
Another conjugate is a D-amino acid oxidase conjugate. This enzyme and its substrates, the D-amino acids, are not found in mammals. The toxic agent produced is hydrogen peroxide. Another conjugate is an α-glycerol phosphate oxidase conjugate. This enzyme is not found in mammals and its substrate, L-α-glycerol phosphate, is found only inside of cells, not outside them. This particular conjugate most likely functions by attachment to the exterior of a cell acting upon exogenously added substrate, which does not cross cell membranes.
Attachment of the various enzymes to the target cell binding protein may be achieved by a variety of means. PCT Application No. PCT/GB86/00711, filed November 21, 1986, published June 4, 1987, Publication No. WO 87/03205, Starkie - inventor and European Patent No. 0 088 695, to Cytogen, both disclose such means. However, the preferred aspect of such attachment is that it is preferably stable to the physiological conditions present during administration to a patient and transport to the site of action. In addition, the attachment is preferably stable to the conditions present at the site of action, particularly to the concentration of hydrogen peroxide present in the immediate vicinity when the enzyme is fully functional. Covalent attachment of the enzyme to a linker molecule is preferable for such stability. Such linking reactions are preferably achieved at a position on the enzyme and under conditions which do not affect the function of the catalytic site of the enzyme and on the antibody at a site which maintains the specificity and affinity of the antigen binding site. The linker molecule may be of a variety of types depending upon the specific sites of attachment to the enzyme and the antibody. The preferred features are that the bond formed is preferably stable to all conditions which the therapeutic agent encounters and that the linker molecule itself preferably does not have reactive groups which would result in its degradation in vivo . The order of reaction would be determined by the specific chemistries of bonding used and could either follow the sequence of attaching the linker to the enzyme and finally to the antibody, or attaching the linker to the antibody followed by attachment to the enzyme.
The enzyme-antibody ratio is preferably about 1:1. Excess enzyme is generally to be avoided.
An enzyme-linker-antibody conjugate meeting the requirements described above would produce hydrogen peroxide in close proximity to the targeted cell. In addition, the hydrogen peroxide produced would be free to diffuse to all adjacent cells. Given the known heterogeneity of tumor cells, this would enhance the effectiveness of such a conjugate as a therapeutic agent. Even highly efficacious, specifically targeted cytotoxic agents which act directly on cells have the shortcoming that they will kill only those cells to which they attach. Surrounding cells which may be neoplastic, but lack the specific epitope targeted, will not be killed. The only solution to this problem using this specific targeting technique is to create a bank of antibodies which will locate all tumor cells. This is a more complex solution and may not be possible when small tumor cell populations are involved. The present invention would solve the problem of tumor cell heterogeneity by killing all cell adjacent to targeted cells. Some normal cells may also be killed, but this would be a very minor side effect compared to thorough destruction of all tumor cells.
The conjugates are preferably targeted to sites which are not rapidly internalized, since this would not allow for killing of adjacent heterogenous tumor cells and would very likely result in inactivation of the oxidase. These conjugates, once attached on the exterior of the cells, preferably utilize substrates which are not normally found in the body fluids filling the extracellular spaces but can diffuse to the site of attachment of the conjugate. Such substrates can include molecules normally found within cells, but not external to them, molecules not normally found in the body, or molecules found in the body in vivo but normally in low enough concentrations that no toxicity is produced by reaction with the oxidases.
A corollary to the requirement that the substrate be not normally found external to cells in the body is that the specific enzyme itself preferably does not occur naturally in humans.
For each of the specific conjugates described previously, the enzyme portion of the conjugate would not produce toxic agent (hydrogen peroxide) until desired. For therapeutic treatments involving these conjugates, the procedure would involve administering the conjugate into the blood, allowing ample time for the conjugate to seek and attach to its specific target and for excess or unattached conjugate to be cleared from the general circulation by action primarily of the liver and kidneys. After such time, a dose of the enzyme's substrate would be injected into the blood at a concentration adequate for enzyme activity without side effects (if any) in the body from the presence of the substrate.
Glycerol phosphate and galactose are normal metabolites and can be administered at a fairly high dose without showing side effects. Although ethanol is not a normal metabolite, it will be metabolized to fat and its side reactions are generally regarded as pleasant. D- amino acids do not normally occur in humans. If at all, only a slight inhibitory reaction of the normal human enzymes which act on the L-amino acid form of the D-amino acid might be expected. This inhibitory reaction could possibly be overcome by simultaneous administration of a higher dose of the equivalent L-amino acid. Treatment regimes can be determined based on the life of the enzyme conjugate, the concentration of the substrate, the reaction rate of the enzyme, and the like. Since hydrogen peroxide is a general cytotoxic agent, meaning that it will kill all cell types, the generating enzyme could be linked to any target cell binding protein. Thus, an enzyme-linker conjugate could be prepared as a general agent for attachment to any antibody or antibody fragment of the desired specificity. Polyclonal antibodies to viruses or bacteria, for example, could also be attached in like manner. Specific enzyme-linker conjugates could also be prepared for attachment to other types of target cell binding proteins, such as hormones, growth factors, binding proteins of various types, and the like It would therefore be possible to use the present invention for destroying a certain population of T cells or B cells in the body, for example, or to "purify" a culture of cells by killing a contaminating population having a specific affinity which can be exploited. Such conjugates, using a variety of linkers for various purposes is also an aspect of the present invention.
EXAMPLES Example 1 - Preparation of Oxidase-Antibody Conjugates
Each of ethanol oxidase, galactose oxidase, D-amino acid oxidase, and α-glycerol oxidase is conjugated to monoclonal antibody 9.2.27 by the following procedure. Thiolation of the Oxidase
To a solution containing 48 nmol of the oxidase in 0.75 ml of 10 mM triethanolamine, 0.2 M NaCl (pH 8.0) is added 7.5 μl of 0.1 M 2-iminothiolane (in 0.5 M triethanolamine, pH 8.2). The reaction is run on ice under 2 for two hours. The reaction mixture is gel filtered on a PD-10 column (Pharmacia) equilibrated in 0.1 M potassium phosphate, 1 mM EDTA (pH 7.3). The solution is kept on ice under 2 and is reacted with SMCC derivatized monoclonal antibody as described below. SMCC Derivatization of Antibody To 75 nmol (11.3 mg) of antibody 9.2.27 in 1 ml phosphate buffered saline (pH 7.0) is added 15 μl of a 25 mM solution of SMCC (succinimidyl-4- (N-maleimidomethyl)- cyclohexane-1-carboxylate) . The reaction is allowed to proceed for one hour at room temperature. The mixture is centrifuged and then gel filtered on a PD-10 column equilibrated in 0.1 M potassium phosphate (pH 6.0). Preparation of conjugate
To 34 nmol of the thiolated oxidase is added 34 nmol of the SMCC-derivatized monoclonal antibody. The reaction is allowed to proceed on ice under 2 for 2 hours and then overnight at 4°C. The reaction is stopped by the addition of excess (700 nmol) of 2-mercaptoethanol.
The conjugate mixture is gel filtered on a PD-10 column equilibrated in 10 mM MES (pH 6.0) . The void volume eluate is centrifuged and applied to a column (4 x 1 cm) of S-Sepharose equilibrated in 10 mM MES (pH 6.0). The column is washed with equilibration buffer and the conjugate is eluted with an appropriate eluent depending on the oxidase, e.g. 10 mM MES, 0.2 M NaCl (pH 6.0). If necessary, to the conjugate eluate is added 200 μl of a 1 mM solution of cofactor for the particular oxidase in the conjugate.
The conjugate is further purified by chromatography on a column (60 x 2.6 cm) of Sephacryl S-300 HR equilibrated in 0.1 M potassium phosphate, 0.05 M NaCl
(pH 7.0). Those fractions which contained 1:1 conjugate are pooled and concentrated by ultrafiltration.
Concentration and activity will be different for each conjugate.
After purification, each conjugate is assayed and found to be a 1:1 adduct of the enzyme and antibody. Example 2
Each of the conjugates prepared in Example 1 is evaluated for in vitro cytotoxic activity using the following procedure.
104 M21-UCLA melanoma cells per well are allowed to grow in 9β-well plates in a 10% CO2 atmosphere at 37°C in 100 μl of RPMI 1640, 10% FBS medium. After 24 hours, the nutrient is taken off and replaced by 100 μl of RPMI 1640, free of the substrate for the conjugate oxidase, containing varying concentrations of the immunoconjugate and a 10-fold activity excess of catalase. Catalase is an enzyme which acts to break down hydrogen peroxide into oxygen and water and serves to prevent cytotoxic effects during the binding step. The immunoconjugates are formed using enzyme and 9.2.27 monoclonal antibody, as indicated in Example 1. The immunoconjugate and catalase containing nutrient is removed 30 minutes later and the wells are rinsed three times with the original medium and the cells are allowed to continue to grow in the original medium, to which 2mM of substrate for the conjugate oxidase is added. After 24 hours, 10 μl of 1 μCi - -thymidine containing medium is added in order to measure thymidine uptake. Thymidine is incorporated into DNA and thymidine uptake is used to measure DNA synthesis which relates to cell viability. After another day of growth the plates are shock frozen, then thawed and the individual well contents passed through glass fiber filters. The radioactivity is determined and taken as a measure of cell viability.
The results of the in vitro assay show a high level of cytotoxicity activity for each conjugate. Example 3
Each of the conjugates prepared in Example 1 is evaluated for in vivo binding specificity and affinity by the following procedure.
Thymus deficient BALBc (nude/nude) mice are subcutaneously injected with 2x106 M21-UCLA melanoma cells. After two weeks, 3 μCi of I125iodinated immunoconjugate is injected into the tail vein. After 48 hours the animals are sacrificed and the radioactivity in individual organs is determined. The immunoconjugates are formed using enzyme and 9.2.27 monoclonal antibody following the procedures discussed in Example 1.
The in vivo biodistribution data obtained with tumor bearing nude mice also shows that each conjugate has a high degree of binding specificity and affinity. Further, the data indicates that for each conjugate, any unbound conjugate is cleared from the body as indicated by the low levels of conjugate found in the blood, liver, kidney, spleen and intestine.

Claims

CLAIMSWhat is claimed is:
1. A composition for producing localized cytotoxic effects on targeted cells comprising: a conjugate of oxidase bound to a target cell binding protein, said conjugate substantially retaining the binding specificity and binding affinity characteristics of said target cell binding protein and at least about 50% of the catalytic activity of said oxidase, and said oxidase having a substrate which is not normally present in the surroundings of said targeted cells.
2. The composition of claim 1, wherein said oxidase is a member of the group consisting of ethanol oxidase, galactose oxidase, D-amino acid oxidase, and α-glyceryl phosphate oxidase.
3. The composition of claim 1, wherein said target cell binding protein is a member of the group consisting of monoclonal antibodies, polyclonal antibodies, antibody fragments, hormones, growth factors, and binding proteins.
4. The composition of claim 1, wherein said target cell binding protein is a monoclonal antibody.
5. The composition of claim 1, wherein said target cell binding protein is a fragment of a monoclonal antibody.
6. The composition of claim 1, wherein said oxidase is bound to said target cell binding protein via a linker molecule.
7. A method of producing localized cytotoxicity on targeted cells which compromises: combining an effective amount of an agent for producing localized cytotoxic effects on targeted cells and a pharmaceutically acceptable carrier therefor, said agent compromising a conjugate of oxidase bound to a target cell binding protein, said conjugate having substantially the binding specifity and binding affinity characteristics of said target cell binding protein and the catalytic activity of said oxidase, said oxidase having a substrate which is not normally present or otherwise available in the extracellular spaces of said target cells, said oxidase catalyzing a reaction, which results in the formation of hydrogen peroxide in the vicinity of said targeted cells, said hydrogen peroxide causing the destruction of said targeted cells and cells in the vicinity of said targeted cells, administering said combined agent and vehicle; allowing sufficient time for said target cell binding protein of said agent to seek and bind to its target cell; permitting or causing unbound amounts of said agent to be cleared; and thereafter administering a dose of said oxidase substrate which is not normally present or otherwise available in the extracellular spaces of said target cells in an amount sufficient to produce cytotoxic concentrations of hydrogen peroxide adjacent said target cells.
8. The method of claim 7, wherein said targeted cells are hosted in a mammalian host.
9. The method of claim 7, wherein said agent is administered by a technique selected from the group consisting of topical administration, intravenous administration, subcutaneous administration and intraperitoneal administration.
10. The method of claim 8, wherein unbound amounts of said agent are cleared by a mammalian host.
11. The method of claim 7, wherein said targeted cells are in a cell culture i.n vitro.
12. The method of claim 7, wherein said dose of said substrate is an effective concentration adequate for oxidase activity while limiting side effects from the presence of said substrate.
PCT/US1990/001527 1989-06-30 1990-03-21 Antibody-oxidase conjugates with non-systemic substrates WO1991000108A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37404889A 1989-06-30 1989-06-30
US374,048 1989-06-30

Publications (1)

Publication Number Publication Date
WO1991000108A1 true WO1991000108A1 (en) 1991-01-10

Family

ID=23475040

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/001527 WO1991000108A1 (en) 1989-06-30 1990-03-21 Antibody-oxidase conjugates with non-systemic substrates

Country Status (3)

Country Link
EP (1) EP0449998A4 (en)
AU (1) AU5732290A (en)
WO (1) WO1991000108A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5490988A (en) * 1990-10-05 1996-02-13 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Delivery of therapeutic agents to a target site
AU672431B2 (en) * 1992-10-02 1996-10-03 Behringwerke Aktiengesellschaft Fusion proteins for prodrug activation
WO2000036094A1 (en) * 1998-12-11 2000-06-22 Unilever N.V. Bleaching enzymes and detergent compositions comprising them

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496539A (en) * 1982-02-01 1985-01-29 Massachusetts Institute Of Technology Method for treating cancer using galactose-specific lectins
WO1987003205A1 (en) * 1985-11-22 1987-06-04 Coral Sociedade Brasileira De Pesquisas E Desenvol Enzyme-coupled antibodies
US4762707A (en) * 1982-03-17 1988-08-09 Sanofi (Societe Anonyme) New conjugates associating, by covalent bond, an enzyme with an antibody, and medicinal associations using the said conjugates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU583854B2 (en) * 1984-09-13 1989-05-11 Cytogen Corporation Antibody therapeutic agent conjugates
WO1990003185A1 (en) * 1988-09-28 1990-04-05 Ideon Corporation Combination enzyme immunotherapeutics

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496539A (en) * 1982-02-01 1985-01-29 Massachusetts Institute Of Technology Method for treating cancer using galactose-specific lectins
US4762707A (en) * 1982-03-17 1988-08-09 Sanofi (Societe Anonyme) New conjugates associating, by covalent bond, an enzyme with an antibody, and medicinal associations using the said conjugates
WO1987003205A1 (en) * 1985-11-22 1987-06-04 Coral Sociedade Brasileira De Pesquisas E Desenvol Enzyme-coupled antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0449998A4 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5490988A (en) * 1990-10-05 1996-02-13 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Delivery of therapeutic agents to a target site
AU672431B2 (en) * 1992-10-02 1996-10-03 Behringwerke Aktiengesellschaft Fusion proteins for prodrug activation
US7060495B2 (en) 1992-10-02 2006-06-13 Behrinwerke Aktienegesellschaft Fusion proteins for prodrug activation
US7273727B2 (en) 1992-10-02 2007-09-25 Behrinwerke Aktiengesellschaft Fusion proteins for prodrug activation
WO2000036094A1 (en) * 1998-12-11 2000-06-22 Unilever N.V. Bleaching enzymes and detergent compositions comprising them
US6277806B1 (en) 1998-12-11 2001-08-21 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Bleaching enzymes and detergent compositions comprising them

Also Published As

Publication number Publication date
EP0449998A1 (en) 1991-10-09
EP0449998A4 (en) 1992-01-15
AU5732290A (en) 1991-01-17

Similar Documents

Publication Publication Date Title
AU627785B2 (en) Vasopermeability-enhancing conjugates
Wu et al. Metal-free bioorthogonal click chemistry in cancer theranostics
CA1304293C (en) Immunoconjugates and methods for their use in tumor therapy
Melton et al. Antibody-enzyme conjugates for cancer therapy
Niculescu-Duvaz et al. Antibody-directed enzyme prodrug therapy (ADEPT): a review
EP0175617B1 (en) Antibody-therapeutic agent conjugates
Thorpe et al. Selective killing of malignant cells in a leukaemic rat bone marrow using an antibody–ricin conjugate
AU7788787A (en) Advanced anticancer therapy and cytotoxic medicaments for its implementation
AU595173B2 (en) Method and use for site-specific activation of substances
JPH09503486A (en) Cytotoxic precursor drug conjugates for anti-cancer therapy
Yemul et al. Selective killing of T lymphocytes by phototoxic liposomes.
KR0185967B1 (en) Site-specific in vivo activation of therapeutic drugs
US6274343B1 (en) Vasopermeability enhancing immunoconjugates
WO1991000112A1 (en) Antibody-lactate oxidase conjugates
Muzykantov et al. Specific killing of human endothelial cells by antibody-conjugated glucose oxidase
US5084560A (en) Immunoconjugates and methods for their use in tumor therapy
WO1991000108A1 (en) Antibody-oxidase conjugates with non-systemic substrates
Philpott et al. Selective binding and cytotoxicity of rat basophilic leukemia cells (RBL-1) with immunoglobulin E-biotin and avidin-glucose oxidase conjugates.
Hay et al. Antibody-directed enzyme-prodrug therapy (ADEPT)
Mukhopadhyay et al. Enhancement of tumouricidal activity of daunomycin by receptor-mediated delivery: in vivo studies
AU754117B2 (en) Targeting and prolonging association of drugs to the luminal surface of the pulmonary vascular endothelial cells
Yemul et al. Phototoxic liposomes coupled to an antibody that alone cannot modulate its cell-surface antigen kill selected target cells
CA2000479C (en) Vasopermeability-enhancing conjugates
JPH09324000A (en) Zygote of factor specifically recognizing interleukin2 receptor with ribonuclease
CA2081281A1 (en) Activation of glucuronide prodrugs by ligand-beta-glucuronidase conjugates for chemotherapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1990908348

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1990908348

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1990908348

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA